Also known as: early Alzheimer's, early Alzheimer’s
A major evidence review of 17 clinical trials involving more than 20,000 participants found anti-amyloid Alzheimer’s drugs had absent or trivial effects on cognitive decline and dementia. The review also said the drugs likely increase the risk of brain swelling and bleeding.
Canada's Drug Agency issued a draft recommendation against public drug plan coverage for lecanemab, an Alzheimer's treatment conditionally approved by Health Canada in October 2025, citing cost concerns despite the drug's ability to slow cognitive decline.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03507257 |
Longitudinal Early-onset Alzheimer's Disease Study Protocol |
ACTIVE_NOT_RECRUITING |
